利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.018 秒)

    Microorganism-related significance index metrics
    2.
    发明授权
    Microorganism-related significance index metrics 有权

    公开(公告)号：US11621055B2

    公开(公告)日：2023-04-04

    申请号：US16645077

    申请日：2018-09-14

    申请人： PSOMAGEN, INC.

    发明人： Zachary Apte ,  Jessica Richman ,  Daniel Almonacid ,  Patricio Lagos ,  Ricardo Castro ,  Paz Tapia

    IPC分类号： G16H50/30 ,  G16B20/00 ,  G16H50/20 ,  C12Q1/689 ,  G01N33/98

    摘要： Embodiments of a method and/or system, such as for characterizing at least one microorganism-related condition, can include: determining a set of associations (e.g., positive associations such as positive correlations, negative associations such as negative correlations, non-associations such as no correlation or minimal correlation, etc.) between a set of microorganism taxa and at least one microorganism-related condition; determining a set of reference features (e.g., reference abundance ranges, etc.) for the set of microorganism taxa; and determining one or more significance index metrics based on the set of associations and the set of reference features.

    Microbiome Byproducts and Uses Thereof
    3.
    发明申请
    Microbiome Byproducts and Uses Thereof 有权

    公开(公告)号：US20220189584A1

    公开(公告)日：2022-06-16

    申请号：US17598954

    申请日：2020-03-27

    申请人： PSOMAGEN INC.

    发明人： Zachary Apte ,  Jessica Richman ,  Daniel Almonacid ,  Valeria Marquez

    IPC分类号： G16B40/20 ,  G16B15/20 ,  A61K35/741 ,  G16B20/00

    摘要： A method for treating a microorganism-related condition in a patient may include detecting microorganisms in a set of samples collected from a population and comparing a relative abundance of and co-occurrence between different microbial taxa in the set of samples. The method further includes associating a change in the relative abundance of or the co-occurrence between the microbial taxa with samples from people, among the population, with the microorganism-related condition and samples from people, among the population, without the microorganism-related condition to determine a target taxa. A blend of bacteriophages is then identified, the blend being configured to remove the target taxa from a community of microorganisms A therapeutic composition comprising the blend is then administered to the patient with the microorganism-related condition.

    Method and system for microbiome-derived diagnostics and therapeutics
    4.
    发明授权
    Method and system for microbiome-derived diagnostics and therapeutics 有权

    公开(公告)号：US10803991B2

    公开(公告)日：2020-10-13

    申请号：US15606743

    申请日：2017-05-26

    申请人： PSOMAGEN, INC.

    发明人： Zachary Apte ,  Jessica Richman ,  Daniel Almonacid

    IPC分类号： G01N33/48 ,  G16H40/67 ,  G16B50/00 ,  C12Q1/68 ,  C12Q1/6883 ,  C12Q1/689 ,  G06F19/00 ,  G16H50/20 ,  G16H20/10 ,  G16B99/00 ,  G16B5/00 ,  G16H50/50 ,  G06G7/58

    摘要： A method for diagnosing and treating an immune microbial dysfunction in a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the immune microbial dysfunction based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset, wherein the characterization is diagnostic of at least one of Crohn's disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ulcerative colitis, and celiac disease; based upon the characterization, generating a therapy model configured to correct the immune microbial dysfunction; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.

    Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
    5.
    发明授权
    Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions 有权

    公开(公告)号：US10803147B2

    公开(公告)日：2020-10-13

    申请号：US15668956

    申请日：2017-08-04

    申请人： PSOMAGEN, INC.

    发明人： Zachary Apte ,  Daniel Almonacid ,  Jessica Richman

    IPC分类号： G01N33/48 ,  G06F19/00 ,  G16B20/00 ,  G16B50/00 ,  G16H50/50 ,  G16H20/00 ,  G06G7/58

    摘要： A method for at least one of characterizing, diagnosing, and treating a locomotor system condition in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the locomotor system condition based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the locomotor system condition; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.

    Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
    6.
    发明授权
    Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions 有权

    公开(公告)号：US10795972B2

    公开(公告)日：2020-10-06

    申请号：US15679697

    申请日：2017-08-17

    申请人： PSOMAGEN, INC.

    发明人： Zachary Apte ,  Daniel Almonacid ,  Jessica Richman

    IPC分类号： G01N33/48 ,  G06F19/00 ,  G16B20/00 ,  G16B50/00 ,  G16H50/50 ,  G16H20/00 ,  G06G7/58

    摘要： A method for at least one of characterizing, diagnosing, and treating a locomotor system condition in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the locomotor system condition based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the locomotor system condition; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.